讲座主题:群体药代药效动力学在新药临床开发中的应用和挑战
讲座时间:2020年9月23日(周三),14:00
直播地址: ,或扫描下方二维码
(打开后记得收藏哦,进入直播间不迷路)
直播间入口,更多干货分享点击了解
在模型引导的药物研发模式和群体药代动力学研究指南(征求意见稿)发布之际,必将在中国医药研发领域掀起新的热潮,刘东阳教授将结合自身丰富的科研和工作经验和案例,给大家分享群体药代药效动力学在新药临床开发中的应用和挑战。
嘉宾介绍
刘东阳 博士,副研究员
北医三院药物临床试验机构副主任;
临床药理与定量药理研究室负责人,副研究员;
刘东阳,博士,北医三院药物临床试验机构副主任,兼任其临床药理与定量药理研究室负责人,副研究员。他在中国协和医科大学获得临床药理学博士,之后依次在美国suny at buffalo药学系、美国fda/cder/ocp2进行pk/pd研究,并于英国曼彻斯特大学获定量药理学硕士,于2019年加入北医三院。到目前为止,他共负责或参与70余项早期临床试验,并在clinical infectious disease, clin. pharmacokinet., lung cancer, eur j pharm sci.等杂志发表sci文章30多篇,主持十三五重大新药创制项目子课题、国自然基金、比尔盖茨梅琳达基金等项目。目前被聘为journal of pharmacokinetics and pharmacodynamics(jpkpd)和endocrine, metabolic & immune disorders - drug targets(emiddt)杂志编委、中国药理学会定量药理委员会副主任委员、药物代谢委员会青委会常委和中国药科大学校外导师等。
主要研究方向包括:
1)代谢性、心血管和肿瘤疾病领域创新药的早期临床开发;
2)临床药理学与定量药理学研究。
近期的科研成果:
1. m zhang, x yao, c cui, x liu, h li, d liu#. commentary to simulation of drug in the lung can be misleading. clin infect dis; 2020. sci 8.313 (epub online ahead) (corresponding author)
2. x yao, f ye, m zhang, c cui, b huang, p niu, x liu, l zhao, e dong, c song, s zhan, r lu, h li#, w tan#, d liu#. in vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (sars-cov-2). clin infect dis 2020. sci 8.313 (epub online ahead) (first co-corresponding author)
3. c cui, m zhang, x yao, s tu, z hou, en vs jie, h li#, s zhang#, d liu#. dose selection of chloroquine phosphate for treatment of covid-19 based on a physiologically based pharmacokinetic model. acta pharm sin b 2020. sci 7.091 (epub online ahead) (first co-corresponding author)
4. x yao, z hou, c cui, m zhang, s tu, h li#, d liu#. updates on the pharmacology of chloroquine against coronavirus disease 2019 (covid-19): a perspective on its use in the general and geriatric population. curr drug metab 2020. sci2.659 (epub online ahead) (first co-corresponding author)
5. c cui, s tu, vsj en, x li, x yao, h li#, d liu#. review on the clinical pharmacology of hydroxychloroquine sulfate for the treatment of covid-19. curr drug metab 2020. sci2.659 (epub online ahead) (first co-corresponding author)
6. l song, z yu, y xu, x li, x liu, d liu#, t zhou#. preliminary physiologically based pharmacokinetic modeling of renally cleared drugs in chinese pregnant women. biopharm drug dispos 2020. sci2.091 (first co-corresponding author)
7. l song, x yao, y liu, w zhong, j jiang, h liu, h zhou, c shi, d liu#, p hu#: translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective sglt2 inhibitor, using allometric scaling, dedrick and pk/pd modeling methods. eur j pharm sci 2020 :105281. sci 3.616 (first co-corresponding author)